A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts).Shubham Pant, Manish R. Patel, Ryan J. Sullivan et al.|Journal of Clinical Oncology|2019Cited by 24